Novo Nordisk (NOVOB DC) Q1 (DKK): Sales 65.35bln (exp. 63.2bln), Wegovy sales 9.38bln (exp. 10.55bln), Net 25.4bln (exp. 23.4bln), EBIT 31.85bln (exp. 29.04bln), EPS 5.68 (exp. 5.23), Gross margin 84.8% (exp. 84.7%)

• Diabetes/Obesity Care sales 61bln, +27%; mainly driven by GLP-1 diabetes sales growth of 32% at CER & Obesity care to 11bln, +42% at CER.
• Number of patients starting on Wegovy in the US has quadrupled Y/Y.
• US demand for Wegovy still exceeds supply.

Q1 Sales Breakdown

• Total GLP-1 34.98bln (exp. 34.78bln, prev. 26.7bln)
• Injectable GLP-1 29.9bln (prev. 22.45bln)
• Ozempic 27.8bln (prev. 19.6bln)
• Victoza 2.16bln (prev. 2.8bln)
• Rybelsus 5bln (preb. 4.35bln)
• Wegovy 9.37bln (prev. 4.5bln)
• Saxenda 1.65bln (prev. 3.27bln)

FY Guidance

• Sales +19 to +27% (exp. +25.9%) at CER
• Operating Profit +22% to +30% at CER.

via Novo Nordisk